Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation (Q24235112)

3

0 references

Saskia Middeldorp

7

0 references

Heather O. Dickinson

8

0 references

Elie A Akl

1

0 references

Victor E D Yosuico

4

object named as

Victor E D Yosuico

0 references

Sameer Gunukula

2

object named as

Sameer Gunukula

0 references

Frederiek F van Doormaal

5

object named as

Frederiek F van Doormaal

0 references

author name string

Saskia Kuipers

6

0 references

Andrew Bryant

Cochrane Database of Systematic Reviews

9

0 references

publication date

13 April 2011

0 references

published in

0 references

cites work

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Low-molecular-weight heparin and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Do low-molecular-weight heparins improve the survival of cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Increasing the efficiency of cancer chemotherapy with heparin: "clinical study".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Heparin and chemotherapy in the management of inoperable lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Does low-molecular-weight heparin influence cancer-related mortality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Low molecular weight heparins could be important in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? An urgent call for research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Heparin-induced thrombocytopenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Can low-molecular-weight heparins improve outcome in patients with cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Heparin treatment of malignancy: the case for clinical trials in colon cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Low dose intravesical heparin as prophylaxis against recurrent noninvasive (stage Ta) bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Heparin and cancer revisited

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Hemostasis and malignancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Antidepressants for old people. Research on antidepressants in the elderly population is scarce

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

[Risk and prevention of thromboembolism complications in gynecologic malignancies]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Heparin for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021

Antithrombotic therapy in cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006652.PUB3

7 January 2021